Back to search

Article

Exploring the Heterogeneity of HER2 gene status and Expression in Non-Positive Breast Cancer Patients: Insights from Immunohistochemistry and Fluorescence In Situ Hybridization

2024-10-22

Abstract excerpt

<title>Abstract</title> <p>Breast cancer became the most prevalent malignancy among women, and HER2 expression status is critical for treatment decisions. With the emergence of ADC drugs, HER2 low-expressing patients who previously did not respond well to traditional anti-HER2 therapies may now benefit. In this study, we evaluated HER2 expression in 349 HER2-non-positive breast cancer patients using immunohistoch...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
57da92cc-eafb-5968-96c1-3cd3ff14f1f7
DOI
10.21203/rs.3.rs-5035261/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Exploring the Heterogeneity of HER2 gene status and Expression in Non-Positive Breast Cancer Patients: Insights from Immunohistochemistry and Fluorescence In Situ HybridizationDOI 10.21203/rs.3.rs-5035261/v1
HER2 Low, Ultra-low, and Novel Complementary Biomarkers: Expanding the Spectrum of HER2 Positivity in Breast CancerSemantic proximity
The trichotomy of HER2 expression confers new insights into the understanding and managing for breast cancer stratified by HER2 statusSemantic proximity
Evolving concepts in HER2 evaluation in breast cancer: Heterogeneity, HER2-low carcinomas and beyond.Semantic proximity
Unveiling the mysteries of HER2-low expression in breast cancer: pathological response, prognosis, and expression level alterationsSemantic proximity
Clinicopathological features and prognosis of HER2 low-expression breast cancer: a single-center retrospective studySemantic proximity
Do HER2-Low Tumors Have a Distinct Clinicopathologic Phenotype?Semantic proximity
Unraveling the clinicopathological and molecular changes induced by neoadjuvant chemotherapy and endocrine therapy in hormone receptor-positive/HER2-low and HER2-0 breast cancerSemantic proximity
American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast CancerSemantic proximity
Updated 2013 College of American Pathologists/American Society of Clinical Oncology (CAP/ASCO) guideline recommendations for human epidermal growth factor receptor 2 (HER2) fluorescent in situ hybridization (FISH) testing increase HER2 positive and HER2 equivocal breast cancer cases; retrospective study of HER2 FISH results of 836 invasive breast cancersSemantic proximity
Integrative genomic and transcriptomic analyses illuminate the ontology of HER2-low breast carcinomas.Semantic proximity
Prognostic Value of HER2-Low Expression in Non-Metastatic Triple-Negative Breast Cancer and Correlation with Other BiomarkersSemantic proximity
Molecular and clinical traits of HER2-low breast cancer patients and their relationship with neoadjuvant treatment effectiveness.Semantic proximity
Select a neighboring publication to make it the new centre.